Childhood cancers: open trials in Netherlands

120 open trials have a site in Netherlands. Registry data; only the trial team decides who can take part.

NCT05384626
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Trial Treatment · Phase 1/2 · Nuvalent Inc.
Netherlands Cancer Institute, Amsterdam · Universitair Medisch Centrum Groningen, Groningen
Registry updated 2026-11-06
NCT07223021
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Trial Treatment · Phase 3 · Memorial Sloan Kettering Cancer Center
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-11-05
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-11-03
NCT04924075
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Universitair Medisch Centrum Utrecht (Site 1530), Utrecht
Registry updated 2026-11-03
NCT03435796
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Trial Treatment · Phase 2/3 · Celgene
Amsterdam UMC Stichting, Amsterdam · Academisch Ziekenhuis Maastricht, Maastricht · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht · Universitair Medisch Centrum Utrecht, Utrecht
Registry updated 2026-11-02
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-30
NCT07570173
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Amsterdam UMC Stichting, Amsterdam · Sint Antonius Ziekenhuis Stichting, Nieuwegein · Radboud universitair medisch centrum Stichting, Nijmegen · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Rotterdam · Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-30
NCT07630974
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-30
NCT05376891
Met Non Small Cell Cancer Registry (MOMENT)
Research · EMD Serono Research & Development Institute, Inc.
VU Medisch Centrum, Amsterdam · Universitair Medisch Centrum Groningen - Department of Medical Oncology, Groningen · Leiden University Medical Center, Leiden · Z.O.L. Campus Sint Jan (975), Roosendaal · Erasmus MC, Rotterdam
Registry updated 2026-10-29
NCT06803147
"Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillance is Stopped. The BLISS Project.
Research · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Antoni van Leeuwenhoek - Centrum voor Vroegdiagnostiek (Barrett Coordination Centre), Amsterdam
Registry updated 2026-10-29
NCT04855656
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Trial Treatment · Phase 1 · Debiopharm International SA
Universitair Medisch Centrum Groningen, Groningen
Registry updated 2026-10-28
NCT07476729
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Trial Treatment · Phase 3 · Charite University, Berlin, Germany
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-26
NCT07871864
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Trial Treatment · Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
University Medical Center Groningen, Groningen · Leiden University Medical Center, Leiden · Radboud University Medical Center, Nijmegen · Princess Máxima Center for Pediatric Oncology, Utrecht
Registry updated 2026-10-26
2022-501454-11-00
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Trial Treatment · Phase 3 · GPOH gGmbH
Princess Máxima Center for Pediatric Oncology, Utrecht
Registry updated 2026-10-21
NCT07133490
INTERACT Stomach-II
Trial Treatment · Phase 2 · Erasmus Medical Center
Antoni van Leeuwenhoek, Amsterdam · Catharina hospital, Eindhoven · Erasmus MC, University Medical Center Rotterdam, Rotterdam
Registry updated 2026-10-21
NCT07291102
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Trial Treatment · Phase 3 · Nationwide Children's Hospital
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-20
NCT05327894
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Trial Treatment · Phase 3 · Princess Maxima Center for Pediatric Oncology
Princess Máxima Center for Pediatric Oncology, Utrecht
Registry updated 2026-10-19
2023-506546-23-00
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-16
NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Trial Treatment · Phase 2 · Novartis Pharmaceuticals
Utrecht
Registry updated 2026-10-15
NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Trial Treatment · Phase 1/2 · Incyte Biosciences International Sàrl
Princess Máxima Center for Pediatric Oncology, Utrecht
Registry updated 2026-10-09
NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Trial Treatment · Phase 1/2 · Syndax Pharmaceuticals
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-09
NCT06376162
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Trial Treatment · Phase 1 · PedAL BCU, LLC
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-09
NCT07866547
Off-line Adaptive Proton Therapy
Research · University Medical Center Groningen
University Medical Center Groningen, Groningen
Registry updated 2026-10-08
2025-522019-40-00
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Trial Treatment · Phase 1/2 · Novartis Pharma AG
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-06
NCT06941272
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Prinses Maxima Centrum voor Kinderoncologie B.V., Utrecht
Registry updated 2026-10-06

All Childhood cancers trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error